MedTrace Logo

Actos Now for Prevention of Diabetes (ACT NOW)

NCT00220961 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2016-08-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone tablets - 45 mg/day

DRUG

Placebo

Placebo tablets similar to pioglitazone tablets - 1 tablet/day

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • Takeda Pharmaceuticals North America, Inc.

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Ralph A. DeFronzo, M.D. · Texas Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220961 on ClinicalTrials.gov